Navigation Links
OncoSec Medical to Present at the 25th Annual Roth Conference
Date:3/14/2013

erapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... 11, 2011 MonoSol Rx, a specialty pharmaceutical ... platform, in collaboration with APR Applied Pharma Research ... FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is ... Company made the strategic decision to reacquire the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Systemic ... and hope to market ... order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Match for Long-Term Care, GREENSBORO, N.C., ... announces that it successfully completed its,Discovery-180 technology ... Inc. ( http://www.foxlearningsystems.com ), a leading e-learning,organization ... is the innovator,of the Real Life, Real ...
... Enhance Collaboration and Partnership with CDC, CAMBRIDGE, ... and technical assistance firm, this month opened an ... services,to the U.S. Centers for Disease Control and ... substantial client of our firm for many years,",said ...
... going down the plughole: that,s how the British emerge from ... in Britain are particularly guilty of wasting shower water and ... Royal Society of Chemistry . , But men in Britain ... about what they wash down the drain. The most glaring ...
... join with Blue Cross and Blue Shield companies ... WASHINGTON, July 14 Recognizing that chronic,illness ... employers are,taking a "hands on" approach to improving ... smoking, obesity, and disease prevention,and management. At a ...
... CARLSBAD, Calif., July 14 The Chopra ... Deepak Chopra, M.D. and,David Simon, M.D. has ... -- a custom-blend oil treatment based on ... is the newest addition to The,Chopra Center,s ...
... first, scientists at Sydney,s Centenary Institute have mapped the ... the potential to turn the way we discover new ... for new treatments. , "These membrane proteins are the ... increased,understanding of them is vital for future drug discoveries," ...
Cached Medicine News:Health News:Fox Learning Systems Selects Prymak's Discovery-180(TM) Technology Assessment to Guide Search for New LMS 2Health News:Fox Learning Systems Selects Prymak's Discovery-180(TM) Technology Assessment to Guide Search for New LMS 3Health News:Abt Associates Opens Atlanta Office 2Health News:British showers most wasteful and inconsiderate in Western Europe 2Health News:Employers Take Active Role in Promoting Workplace Wellness 2Health News:Employers Take Active Role in Promoting Workplace Wellness 3Health News:The Chopra Center for Wellbeing Introduces Ayurnas: A Soothing Natural Remedy for Sinus Congestion, Chronic Headaches, and Cold Symptoms 2Health News:Discovery first step to new therapies 2
Conducting disposable tips provide cross-contaminationfree pipetting for sensitive applications such as PCR setup....
... to optimize the accuracy and precision of ... is widely recognized by customers throughout the ... over the years and now covers a ... including filter tips, certified pure tips, stepper ...
... the Finntip Wide is designed especially for ... genomic DNA. This tip eliminates the mechanical ... excellent for use with extremely viscous liquids. ... of the orifice is 1.1 mm or ...
Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels...
Medicine Products: